Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Decreased Body Temperature01:29

Decreased Body Temperature

A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by sustained extreme cold exposure, and severe...
Increased Body Temperature01:25

Increased Body Temperature

A body temperature above  38°C  (100.4 °F) is known as fever or pyrexia, and a person with fever is termed 'febrile.' Typically, the hypothalamus, a part of the brain that acts as the body's thermostat, regulates body temperature through a thermoregulatory setpoint. It receives signals from cold and warm thermal receptors throughout the body and adjusts the body's temperature accordingly. Fever occurs when this hypothalamic setpoint is altered, usually in response to an infection or illness.
Immunoprecipitation01:20

Immunoprecipitation

Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diabetes mellitus and pernicious anemia: interrelated therapeutic triumphs discovered shortly after William Osler's death.

Proceedings (Baylor University. Medical Center)·2020
Same author

Early stage IgD multiple myeloma in a 50-year-old man.

Proceedings (Baylor University. Medical Center)·2020
Same author

Singular Selves. Historical Issues and Contemporary Debates in Immunology. A. M. Moulin and A. Cambrosio, eds.Singular Selves. Historical Issues and Contemporary Debates in Immunology. A. M. Moulin and A. Cambrosio, eds. Amsterdam: Elsevier, 2001,303 p., Euro 49.

Canadian bulletin of medical history = Bulletin canadien d'histoire de la medecine·2017
Same author

Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.

British journal of haematology·2016
Same author

John M. T. Finney: distinguished surgeon and Oslerphile.

Proceedings (Baylor University. Medical Center)·2016
Same author

Advance care planning knowledge and documentation in a hospitalized cancer population.

Proceedings (Baylor University. Medical Center)·2013
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Heating up cold agglutinins.

Marvin J Stone1

  • 1Baylor Sammons Cancer Center, Dallas, TX, USA.

Blood
|October 30, 2010
PubMed
Summary
This summary is machine-generated.

Combination therapy with fludarabine and rituximab shows high response rates in patients with chronic cold agglutinin disease (CAD). Durable responses suggest a significant advance for this challenging condition.

More Related Videos

Determining the Reactivity and Titre of Serum using a Haemagglutination Assay
05:59

Determining the Reactivity and Titre of Serum using a Haemagglutination Assay

Published on: January 29, 2010

Comparison of Tobacco Host Cell Protein Removal Methods by Blanching Intact Plants or by Heat Treatment of Extracts
11:06

Comparison of Tobacco Host Cell Protein Removal Methods by Blanching Intact Plants or by Heat Treatment of Extracts

Published on: August 8, 2016

Related Experiment Videos

Last Updated: Jun 7, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Determining the Reactivity and Titre of Serum using a Haemagglutination Assay
05:59

Determining the Reactivity and Titre of Serum using a Haemagglutination Assay

Published on: January 29, 2010

Comparison of Tobacco Host Cell Protein Removal Methods by Blanching Intact Plants or by Heat Treatment of Extracts
11:06

Comparison of Tobacco Host Cell Protein Removal Methods by Blanching Intact Plants or by Heat Treatment of Extracts

Published on: August 8, 2016

Area of Science:

  • Hematology
  • Immunology

Background:

  • Chronic cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia.
  • Current treatment options for CAD have limitations in efficacy and durability.

Discussion:

  • The study by Berentsen and coworkers investigates the efficacy of fludarabine and rituximab combination therapy in CAD.
  • This combination targets both B-cells and underlying autoimmune mechanisms implicated in CAD.

Key Insights:

  • The combination therapy demonstrated a high response rate in patients with chronic cold agglutinin disease.
  • A notable proportion of patients experienced durable responses, indicating sustained clinical benefit.

Outlook:

  • These findings represent a significant potential advancement in managing chronic cold agglutinin disease.
  • Further confirmation and long-term studies are warranted to fully establish this therapeutic approach.